Oral JAK inhibitors After considering risks and possible benefits may use in adults and adolescents w moderate to severe AD refractory to or who can t tolerate use mid to high potency topical tx and systemic tx including a previously recommended biologic

<b>Oral JAK inhibitors:</b> After considering risks and possible benefits, may use in adults and adolescents w/ moderate to severe AD refractory to or who can’t tolerate/use mid- to high-potency topical tx and systemic tx including a previously recommended biologic. AAAAI/ACAAI conditionally recommends replacing systemic tx w/ one of the following (in alpha order): <a href=https://online.epocrates.com/e/deeplink/drugs/10a10684/Cibinqo><u>abrocitinib</u></a> 100-200 mg (≥12 yo); <a href=https://online.epocrates.com/e/deeplink/drugs/10a8131/Olumiant><u>baricitinib</u></a> 2-4 mg (not FDA approved for AD); <a href=https://online.epocrates.com/e/deeplink/drugs/10a8824/Rinvoq><u>upadacitinib</u></a> 15-30 mg (≥12 yo). However, in most pts w/ mild to moderate AD, risk of oral JAK inhibitor may be higher than topical one. AAAAI/ACAAI conditionally recommends <i>against</i> azathioprine.¹